Al­ler­gan, So­sei halt glob­al de­vel­op­ment for Alzheimer’s drug fol­low­ing tox­ic re­ac­tion in a non-hu­man pri­mate

Al­ler­gan and So­sei have hit the brakes on an in­ter­na­tion­al de­vel­op­ment pro­gram fea­tur­ing a key Alzheimer’s drug fol­low­ing an “un­ex­pect­ed tox­i­col­o­gy find­ing” for one of the non-hu­man pri­mates it test­ed the ther­a­py on.

The drug is HTL0018318, a mus­carinic M1 re­cep­tor ag­o­nist that Al­ler­gan part­nered on when it signed a de­vel­op­ment deal with So­sei’s UK sub­sidiary Hep­tares which was worth close to $840 mil­lion, plus bil­lions in po­ten­tial sales bonus­es. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER